HY 015
Alternative Names: Anti-BCMA CAR-T cell therapy - Juventas Cell Therapy; HY-015Latest Information Update: 28 Jul 2023
At a glance
- Originator Juventas Cell Therapy
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Multiple-myeloma in China (Parenteral)
- 24 Jun 2019 Preclinical trials in Multiple myeloma in China (Parenteral) (Juventas Cell Therapy pipeline, June 2019)